personalized treatment
Personalized Treatment
Our Main Idea is to provide customised treatment options to each person. Many patients do not respond well to current therapies, therefore there is a need personalized treatment.
 
Our tests will guide you and your health care providers in choosing the right treatment plan
RGCC
RGCC Group is a specialised medical genetics company and experts in developing, providing personalised cancer tests for patients and doctors. RGCC uses cutting-edge technology to design their tests which help to discover, analyse and screen cancer cells at every step of the disease.
Early detection
Different Cancers ONE test
Cancer can be developed in any possible organ of the human body. Any type of cancer, any stage of cancer, Multiple cancers with unknown primary origin. ONE stop diagnosis with a simple blood test.
 
We provide you with all the information you require for the best treatment options.
CTC’S & CSC’S
CTC’s & CSC’s
CTC’s and CSC’s can predict the treatment response and monitor the cancer progression. CTC’s and CSC’s can be used to search for specific biomarkers that can identify a tumour’s location, and predict potential metastases.
 
Our tests are designed in such way to understand the various aspects of cancer and helps the doctors in creating the accurate treatment plan
Early detection of Cancer/Relapse/Recurrence can “make a real difference..”
Pre-procedure counselling is offered to determine the benefits of CTC tests..
Best Quality tests for you

RGCC CAMBISEQ™

RGCC cancer analysis, mutational burden and instability sequencing (CAMBISeq) provides next- generation sequencing analysis on both DNA and RNA. RGCC CAMBISeq can help to identify variants in more than 500 genes,

See more >

aCGH Test

The array comparative genomic hybridisation (aCGH) test is used to identify abnormalities in a genome,when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer.

See more >

Metastat RGCC Test

Markers on CTCs that point out the potential organ for relapse. It can help practitioners in the prognosis of metastases trends in cancer patients and guide them in the choice of appropriate chemotherapy.

See more >

Immune Frame Test

Profile of humoral and cellular immunity and cachexia. This test uses specific cellular markers and cytokine production to detect the type/types of cells that are responsible for activation / repression of the immune system of host.

See more >

Oncotrail RGCC Test

This test is a tailor made test for a specific type of malignancy such as breast cancer (Oncotrail for Breast), prostate (Oncotrail for Prostate), Colon, Melanoma, Lung, Sarcoma, Gastrointestinal for follow up control.

See more >

Oncotrace RGCC Test

This test will report the number of CTC's, any positive CSC's, and the immunophenotype of these cells.

See more >

Oncocount RGCC Test

This test will report only the number of Circulating Cancer Tumor Cells (CTC's). It does not include any other information concerning the CTC's or Circulating Cancer Stem Cells (CSC's) Immunophenotyping.

See more >

Onconomics Plus RGCC Test

This provides information on the sensitivity or resistance of the patient's tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances.

See more >

Onconomics Extracts Test

This test includes only the assessment of natural substances and plant extracts for any anticancer potency. No chemotherapeutic agents tested and no tumor suppressor genes tested.

See more >

Onconomics RGCC Test

This test includes the chemosensitivity / chemoresistance assessment for cytotoxic drugs, monoclonal antibodies, and small molecules that inhibit specific targets eg. (TKI, etc.). No natural substances tested.

See more >
Information For Patients
We work with cancer patients to provide a range of personalised
tests so you can choose the best treatment.

What Our Doctor's Say:

Dr IoannisPapasotiriou
Dr Ioannis Papasotiriou

Using this test helps oncologists take the possible drug out of chemo selection, increasing the likelihood of successful treatment, and reducing unnecessary toxic side effects by avoiding chemos that would not work

Every cancer patient is unique
Why choose our Tests?

CTC'S COUNT CAN BE CONSIDERED AS A PREDETERMINED PROGNOSTIC FACTOR , TO DETECT EARLY RELAPSE OR RECURRENCE CONDITIONS.

News & events
Find out more about our latest research, trials and education days

Ctcs can play a key role in improving metastatic breast cancer treatment1

Circulating tumour cells (CTCs) can play a crucial role in improving treatments for metastatic breast cancer, scientists have found. The…
Read More

Ctcs can play a key role in improving metastatic breast cancer treatment

Circulating tumour cells (CTCs) can play a crucial role in improving treatments for metastatic breast cancer, scientists have found. The…
Read More